Sturkenboom, MCJM;
Verhamme, KMC;
Nicolosi, A;
Murray, ML;
Neubert, A;
Caudri, D;
Picelli, G;
... Wong, ICK; + view all
(2008)
Drug use in children: cohort study in three European countries.
British Medical Journal
, 337
, Article a2245. 10.1136/bmj.a2245.
![[thumbnail of drug_use_in_children.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) Preview |
Text
drug_use_in_children.pdf Available under License : See the attached licence file. Download (181kB) |
Abstract
Objective To provide an overview of drug use in children in three European countries. Design Retrospective cohort study, 2000-5. Setting Primary care research databases in the Netherlands (IPCI), United Kingdom (IMS-DA), and Italy (Pedianet). Participants 675 868 children aged up to 14 (Italy) or 18 (UK and Netherlands). Main outcome measure Prevalence of use per year calculated by drug class (anatomical and therapeutic). Prevalence of “recurrent/chronic” use (three or more prescriptions a year) and “non-recurrent” or “acute” use (less than three prescriptions a year) within each therapeutic class. Descriptions of the top five most commonly used drugs evaluated for off label status within each anatomical class. Results Three levels of drug use could be distinguished in the study population: high (>10/100 children per year), moderate (1-10/100 children per year), and low (<1/100 children per year). For all age categories, anti-infective, dermatological, and respiratory drugs were in the high use group, whereas cardiovascular and antineoplastic drugs were always in the low use group. Emollients, topical steroids, and asthma drugs had the highest prevalence of recurrent use, but relative use of low prevalence drugs was more often recurrent than acute. In the top five highest prevalence drugs topical inhaled and systemic steroids, oral contraceptives, and topical or systemic antifungal drugs were most commonly used off label. Conclusion This overview of outpatient paediatric prescription patterns in a large European population could provide information to prioritise paediatric therapeutic research needs.
Archive Staff Only
 |
View Item |
